Literature DB >> 23461277

The levonorgestrel-releasing intrauterine system: its effect on the number of hysterectomies performed in perimenopausal women with uterine fibroids.

Rogério Bonassi Machado1, Isadora Matias de Souza, Amanda Beltrame, Carine Rejane Bernardes, Mariana Spagnuolo Morimoto, Narayana Santana.   

Abstract

This prospective observational study was designed to determine the percentage of hysterectomies avoided following insertion of a levonorgestrel-releasing intrauterine system (LNG-IUS) in perimenopausal women with uterine fibroids and a prior indication for surgery. The study also compared the progress of patients using the LNG-IUS with those submitted to hysterectomy, with particular emphasis on the patient's satisfaction with treatment. Sixty perimenopausal patients with uterine fibroids and excessive bleeding referred for hysterectomy were included. After counseling on the possibility of non-surgical treatment, 39 patients opted to use an LNG-IUS while 21 opted for hysterectomy. Continuation of LNG-IUS use and the patient's satisfaction with the chosen procedure were assessed. A secondary analysis evaluated hemoglobin levels, clinical complications, bleeding patterns and uterine volume at ultrasonography over time. After 24 months of follow-up, four of the patients who had opted to use an LNG-IUS were submitted to surgery, while 35 continued using the device, thus avoiding hysterectomy in 89.5% of cases. LNG-IUS users were more satisfied with treatment (p = 0.02) compared to those submitted to hysterectomy. In conclusion, the use of the LNG-IUS enables the number of hysterectomies to be reduced in women with uterine fibroids and is associated with greater satisfaction compared to surgical treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23461277     DOI: 10.3109/09513590.2013.769517

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  6 in total

1.  Putative human myometrial and fibroid stem-like cells have mesenchymal stem cell and endometrial stromal cell properties.

Authors:  Amanda L Patterson; Jitu W George; Anindita Chatterjee; Tyler J Carpenter; Emily Wolfrum; David W Chesla; Jose M Teixeira
Journal:  Hum Reprod       Date:  2020-01-01       Impact factor: 6.918

Review 2.  Contraception During Perimenopause: Practical Guidance.

Authors:  Giovanni Grandi; Pierluigi Di Vinci; Alice Sgandurra; Lia Feliciello; Francesca Monari; Fabio Facchinetti
Journal:  Int J Womens Health       Date:  2022-07-15

Review 3.  Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Authors:  Mohamed Ali; Sara A R; Ayman Al Hendy
Journal:  Expert Rev Clin Pharmacol       Date:  2021-03-15       Impact factor: 5.045

Review 4.  Femilis(®) 60 Levonorgestrel-Releasing Intrauterine System-A Review of 10 Years of Clinical Experience.

Authors:  Dirk Wildemeersch; Amaury Andrade; Norman Goldstuck
Journal:  Clin Med Insights Reprod Health       Date:  2016-08-09

Review 5.  The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids.

Authors:  Wojciech Wrona; Anna Stępniak; Piotr Czuczwar
Journal:  Prz Menopauzalny       Date:  2017-12-30

Review 6.  Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids.

Authors:  Mohamed Ali; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2017-09-01       Impact factor: 4.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.